The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset
Tóm tắt
Từ khóa
Tài liệu tham khảo
Alvir, 1993, Clozapine-induced agranulocytosis. Incidence and risk factors in the United States, N. Engl. J. Med., 329, 162, 10.1056/NEJM199307153290303
Anttila, 2001, A review of the pharmacological and clinical profile of mirtazapine, CNS Drug Rev., 7, 249, 10.1111/j.1527-3458.2001.tb00198.x
de Boer, 1988, Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers, Neuropharmacology, 27, 399, 10.1016/0028-3908(88)90149-9
Cummings, 2014, Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial, Lancet, 383, 533, 10.1016/S0140-6736(13)62106-6
Fenelon, 2000, Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors, Brain, 123, 733, 10.1093/brain/123.4.733
Forsaa, 2010, A 12-year population-based study of psychosis in Parkinson disease, Arch. Neurol., 67, 996, 10.1001/archneurol.2010.166
Fox, 2006, Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease, Arch. Neurol., 63, 1343, 10.1001/archneur.63.9.1343
Fox, 2010, Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease, Can. J. Neurol. Sci., 37, 86, 10.1017/S0317167100009707
French Clozapine Parkinson Study Group, 1999, Clozapine in drug-induced psychosis in Parkinson's disease, Lancet, 353, 2041, 10.1016/S0140-6736(99)00860-0
Friedman, 1996, Comments and reply on Ikeguchi and Kuroda: mianserin treatment of patients with psychosis induced by antiparkinsonian drugs, Eur. Arch. Psychiatry Clin. Neurosci., 246, 106, 10.1007/BF02274901
Hamadjida, 2017, The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset, Psychopharmacology, 234, 905, 10.1007/s00213-017-4530-z
Hely, 2005, Sydney multicenter study of Parkinson's disease: non-l-dopa-responsive problems dominate at 15 years, Mov. Disord., 20, 190, 10.1002/mds.20324
Huot, 2010, Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations, Mov. Disord., 25, 1399, 10.1002/mds.23083
Huot, 2011, Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time, J. Neurosci., 31, 7190, 10.1523/JNEUROSCI.1171-11.2011
Huot, 2012, The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset, PLoS One, 7, e45587, 10.1371/journal.pone.0045587
Huot, 2012, 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with l-DOPA, Neurobiol. Aging, 33, e5
Huot, 2014, UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset, Neuropharmacology, 82, 76, 10.1016/j.neuropharm.2014.01.012
Ikeguchi, 1995, Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs, Eur. Arch. Psychiatry Clin. Neurosci., 244, 320, 10.1007/BF02190411
Kelder, 1997, A comparison of the physicochemical and biological properties of mirtazapine and mianserin, J. Pharm. Pharmacol., 49, 403, 10.1111/j.2042-7158.1997.tb06814.x
Kooyman, 1994, Interaction between enantiomers of mianserin and ORG3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells, Neuropharmacology, 33, 501, 10.1016/0028-3908(94)90081-7
Kurata, 1988, High-performance liquid chromatographic determination of mianserin in plasma and brain and its application to pharmacokinetic studies in the rat, J. Chromatogr., 434, 278, 10.1016/0378-4347(88)80088-4
Lang, 1998, Parkinson's disease. First of two parts, N. Engl. J. Med., 339, 1044, 10.1056/NEJM199810083391506
Nawata, 2016, The pharmacokinetics of mianserin suppositories for rectal administration in dogs and healthy volunteers: a pilot study, J. Pharm. Health Care Sci., 2, 12, 10.1186/s40780-016-0046-7
de Nijs, 1977, Pharmacokinetics of mianserin.hcl (Org GB 94) in the isolated perfused rat liver and in the anasthetized rat, Eur. J. Drug Metab. Pharmacokinet., 21, 10.1007/BF03189313
Parkinson Study Group, 1999, Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease, N. Engl. J. Med., 340, 757, 10.1056/NEJM199903113401003
Pinder, 1983, Pharmacological aspects of mianserin, Acta Psychiatr. Scand. Suppl., 302, 59, 10.1111/j.1600-0447.1983.tb00359.x
Shami, 1983, The pharmacokinetics of mianserin, Br. J. Clin. Pharmacol., 15, 313S, 10.1111/j.1365-2125.1983.tb05880.x
Thomas, 2010, Current use of clozapine in Parkinson disease and related disorders, Clin. Neuropharmacol., 33, 14, 10.1097/WNF.0b013e3181c47168
Visanji, 2006, Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease, Mov. Disord., 21, 1879, 10.1002/mds.21073